anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a new skin cosmetic excellent in skin beautifying effect attributable to the improvement of dry feeling, shortage of glossiness, fine wrinkles, rough skin, etc., and also excellent in safety by using an extract obtained from a specific plant belonging to the family Labiatae. SOLUTION: This cosmetic is obtained by using an extract of catnip belonging to the family Labiatae. Leaves, flowers, stems or a whole plant of catnip is extracted by immersing into a hot medium of an aqueous organic solvent or a hydrated aqueous organic solvent at an immersing temperature from the ambient temperature to the boiling temperature of the extraction medium. Subsequently, the extraction liquid is subjected to suction filtration followed by the concentration under reduced pressure to remove the solvent. Thus, a viscous or exsiccated extract is obtained. Further, the extraction solvent is preferably a hydrated aqueous organic solvent preferably containing >=50wt.% of an aqueous organic solvent such as a monovalent alcohol or acetone. The skin cosmetic is supplied in various kinds of preparations including a skin lotion, an emulsion, a cream, a pack, etc.
The purpose of this study is to optimize blood stem cell mobilization in adults with beta thalassemia major. We seek a method of mobilization that will be safe, with minimum side effects, and that will yield high numbers of blood stem cells. For successful gene therapy of thalassemia, high numbers of genetically modified stem cells will need to be introduced into the patient. Participants will include beta-thalassemia patients who failed to mobilize sufficiently with G-CSF (in our previous protocol) and new patients. In this study we will focus on the safety and effectiveness of mobilization with Mozobil or with Mozobil plus G-CSF. Following mobilization, blood stem cells will be recovered using leukapheresis, a procedure similar to a blood donation, in which mobilized white blood cells are collected from the blood of the patient.

During drug administration and leukapheresis, patients will be hospitalized at George Papanicolaou Hospital in Thessaloniki, Greece. Patients who failed to mobilize in the previous protocol will receive Mozobil and G-CSF and will be hospitalized for 5-8 days for the duration of drug administration and leukapheresis. They will receive G-CSF for several days; Mozobil will be added on the last few days of G-CSF. New patients will receive Mozobil only and will be hospitalized for 2-3 days for drug administration and leukapheresis. Mozobil is administered at 240µg/kg, under the skin. Participants will undergo two or three leukapheresis procedures in a row if low numbers of blood stem cells were recovered in the first (and possibly second) leukapheresis. Participants will be discharged from the hospital the day following the last leukapheresis procedure. Weekly follow-up visits will occur for the next month, either at G. Papanicolaou Hospital, or at the participant's local doctor's office. The total period of study participation is approximately 5 weeks. In the event that Mozobil alone does not cause mobilization of high levels of blood cells, patients will be invited to repeat the protocol three months later, receiving Mozobil and G-CSF.
Subjects assigned to the control group will receive no intervention. They will stay behind the curtained research area for approximately 3 minutes in a seated position.
Methods and compositions are disclosed for the preparation of free radical scavenging polymers and polymer films functionalized with antioxidants. Enzymatic and chemical tailoring of monomers with antioxidants followed by enzymatic polymerization is described. These antioxidant functionalized polymers can increase shelf life and quality of food products, as well as, increase effectiveness of pharmaceutical agents when used as packaging or as coatings on packaging for oxygen sensitive materials. The novel enzymatic covalent coupling of antioxidants to a polymer enhances the free radical scavenging ability of packaging while also inhibiting the escape of the antioxidants, and thus limiting exposure and/or absorption by an individual. In addition to its use in food or pharmaceutical packaging, methods are disclosed for using the antioxidant coupled polymers in a variety of applications including as coatings on the inside of medical devices, such as stents and catheters, which would substantially reduce free radical damage and/or oxygen depletion during medical procedures. Furthermore, through the coupling of antioxidants to biodegradable polymers, controlled delivery and sustained release of an antioxidant to a subject is possible.
The investigators will conduct a randomized controlled trial (RCT) with two different formats of the same systematic review summary (Infographics, PLS). The content of these two formats is based on the same systematic review, but the ways of data presentation will differ: visual presentation in plain language and plain language only. The interventions will be delivered online in November 2016, with members of the consumers' groups for pregnancy and parenting - RODA ("Roditelji u akciji", engl."Parents in action"), which gathers different types of consumers: pregnant women, young mothers and parenting and pregnancy advisors; and the members of the Association for Patients' Rights. The trial will be voluntary and anonymous. The survey will consist of 5 parts, in the following order: 1) one format of the summary (randomly assigned), 2) health numeracy, 3) demographic data 4) comprehension test of the information given in the summary, and 5) user friendliness of information and overall satisfaction with the given summary assessed by survey.
Autoimmune congenital heart block (ACHB) is a passively acquired immune-mediated disease characterized by the presence of maternal antibodies against components of the Ro/SSA and La/SSB ribonucleoprotein complex that mainly affects the cardiac conducting system. ACHB occurs in 2% of women with positive anti-Ro/SSA and anti-La/SSB antibodies and causes a high risk of intrauterine fetal death, neonatal mortality, and long-term sequelae. In this review, we first describe a case of ACHB to provide preliminary knowledge. Then, we discuss the possible pathogenic mechanisms of ACHB; summarize the pregnancy management of patients with positive anti-Ro/SSA and anti-La/SSB antibodies and/or rheumatic diseases, the prevention of ACHB, and the treatment of ACHB fetuses; and propose routine screening of these antibodies for the general population. Careful follow-up, which consists of monitoring the fetal heart rate, is feasible and reassuring for pregnant women with positive anti-Ro/SSA and/or anti-La/SSB antibodies to lower the risk of ACHB in fetuses. Moreover, maternal administration of hydroxychloroquine may be useful in preventing ACHB in pregnant women with anti-Ro/SSA and/or anti-La/SSB antibodies.
The invention provides an aggregate, a preparation method thereof and an insulin oral preparation. In particular to an aggregate formed by assembling chalcogen heterocyclic compounds and insulin. The agglomerates can be further prepared into insulin oral preparations. The oral formulation may be used to reduce blood glucose levels in a mammal as part of a diabetes treatment regimen. The chalcogen heterocyclic compound in the insulin oral preparation prepared by the method can effectively protect insulin against three physiological barriers of an oral intake path, is stable in a gastrointestinal tract environment, and enters a circulatory system from intestinal epithelial cells through dynamic chemical exchange reaction between surface poly-chalcogen molecular bonds and sulfhydryl groups of intestinal mucin in intestinal juice and inner and outer proteins of epithelial cell membranes, so that the effect of reducing blood sugar is achieved. The insulin oral preparation has high bioavailability and good blood sugar reducing effect in mammal body when orally administered, and can be used for treating diabetes.
The patients in the control group accepted routine aspirin and heparin treatment. Two months before pregnancy, 50 mg of aspirin (Chenxin Pharmaceutical, China) was taken orally once a day.
Patients diagnosed with adolescent idiopathic scoliosis participated in sessions twice a week for 8 weeks, with each session lasting 45 minutes. During the sessions, ISST Schroth exercises were combined with dynamic neuromuscular stabilization exercises.
601819 Disclosed is a method for healthcare action sequencing by a bedside device. A patient care area is scanned for tags for entities present in the area such that a given patient is located in the area. In response to detecting a tag for an entity in the area, identity data is read from the tag. Input data (16, 17) is received regarding the given patient by at least one healthcare personnel via a user-interface which is then sent with the input data (16, 17) to a management system that includes a first database storing first rules for how patients with known sets of conditions are to be cared for, a second database (11) storing second rules for how the input data (16, 17) are to be used, and a third database (13) storing third rules relating to procedures and restrictions for the at least one healthcare personnel. Action data is then received for the given patient from the management system based at least in part on the identity data, the input data (16, 17), and at least one of the first rules, the second rules, and the third rules. Information is then displayed on the user-interface based at least in on the received action data.
PURPOSE: To prepare a treating liquid for animal fibers, keratin-based fibers or the like by compounding a surfactant and a diorganopolysiloxane having diester functional groups containing a structural unit expressed by a specified general formula in an aq. medium. CONSTITUTION: A diorganopolysiloxane having diester functional groups having at least one structural unit expressed by formula I per one molecule is compounded in an aq. medium to prepare an aq. emulsion. In the formula I, Z is expressed by formula II (R' is a 1-12C satd. hydrocarbon group, 2-12C univalent alkoxyalkyl group or the like, X is H or methyl group, W is a covalent bond or the like), R is a 1-20C alkyl group or the like, and a is 0, 1, 2. The obtd. aq. emulsion can be preferably used as a coating agent for a cellulose support for cosmetic or dermatological treatment of hair or skin.
OBJECTIVES: Immunotherapy with nivolumab for patients with recurrent/metastatic oral squamous cell carcinoma has not been evaluated. Here, we aimed to examine the efficacy, safety, and prognostic factors of nivolumab in these patients.
MATERIALS AND METHODS: This multicenter retrospective observational study involved patients who received nivolumab between April 2017 and June 2019. The patient characteristics were evaluated for association with progression-free and overall survival. Progression-free and overall survival rates were calculated; parameters that were significant in the univariate analysis were used as explanatory variables. Independent factors for progression-free and overall survival were identified using multivariate analysis.
RESULTS: Totally, 143 patients were included. The overall response and disease control rates were 27.3% and 46.2%, respectively. The median, 1- and 2-year progression-free survival rates were 2.7 months, 25.4%, and 19.2%, respectively; those for overall survival were 11.2 months, 47.3%, and 33.6%, respectively. The independent factors affecting progression-free survival were performance status and immune-related adverse event occurrence, whereas those affecting overall survival were performance status, target disease, and number of previous lines of systemic cancer therapy. Eight patients reported grade ≥3 immune-related adverse events.
CONCLUSION: Nivolumab was effective for recurrent/metastatic oral squamous cell carcinoma treatment and was well tolerated by patients.
Patients that use oronasal face masks in their ordinary care to measure early-stage medical devise-related tissue damage during routine management regimes of NIV. Approximately 150 adult patients of both sexes will be recruited, from facilities that employ oronasal face masks in the routine care.
Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I, MART-1:26-35(27L) peptide vaccine emulsified in Montanide ISA-51 as in arm II, and aldesleukin as in arm III. 1 x 10e9 to 5 x 10e10 IV + 1.0 mg peptide subcutaneously + IL-2 (based on body weight) 125,000 IU/kg/day subcutaneously.
The COVID-19 pandemic has arguably had its greatest impact in rural and other historically hard-to-reach populations. Families in rural and underserved communities experienced COVID-19 infections at a higher rate than did their peers in other groups and experienced disproportionate morbidity and mortality. Without careful design and implementation of resources, children in these areas are also at risk of being disproportionately affected by long-term sequelae of SARS-CoV-2 infections, such as "long COVID" syndromes. Increased frequency and severity of COVID-19 infections, decreased access to health care and supporting services, environmental and social structure factors that exacerbate post-acute sequelae of COVID-19, and increased baseline frequency of health disorders that may complicate post-COVID issues, such as higher rates of obesity, asthma, diabetes, and mental health disorders, all place children and adolescents in under-resourced areas at significant risk. Unfortunately, children and adolescents in these areas have been historically under-represented in clinical research. Not only are fewer studies published with participants in rural and underserved communities, but these studies more often exhibit lower quality, with fewer randomized controlled trials and multicenter studies. This gap not only deprives people in rural and underserved areas of the country of access to cutting-edge therapy, but it also risks "evidence-based" solutions that are not generalizable because they cannot be implemented in the areas disproportionately affected by many health conditions such as long COVID. These factors significantly impede our ability to provide appropriate medical care for underserved communities. This review will discuss the impact of COVID-19 in rural and underserved communities and the factors that must be considered in designing evidence-based long-COVID solutions for children and adolescents in these areas.
A software implemented method for dispensing herbs comprises a platform that uses artificial intelligence (AI) to dispense natural herbs appropriate to the identified health needs of an individual. The method may work together with accessories such as wearables to utilise real data analytics to measure the effectiveness of the prescribed herb(s). This approach ensures that practitioners or herbologists have digital recorded feedback and are only remunerated when their proposed natural herbs are able to help individuals. A mobile based application may be used to access services. The invention includes an automated herb dispensing machine (HDM) that can dispense more than 20-50 different herbs. To activate the HDM, an individual scans their ID allowing access to a customized profile and enables the software in the machine to dispense a concoction/recipe of the herbs according to the ID of the individual. The HDM may come in two models a public dispensing machine and a home dispensing machine.
Participants were treated with peginesatide administered intravenously (IV) every 4 weeks for 24 weeks. Participants were then to be converted back to epoetin alfa administered by IV 3 times a week for 32 weeks.
The present invention discloses a Ginkgolide composition and a method for the preparation thereof. The composition includes two active components, Ginkgolide A and Ginkgolide B, and the weight ratio of Ginkgolide A to Ginkgolide B is 1: (2-9). A strong synergistic effect is found between Ginkgolide A and Ginkgolide B, which has a remarkable application effect on the treatment of cardio-cerebral vascular disease. The invention realizes simultaneous determination for the component content of the Ginkgolides preparation. Experiments show that the Ginkgolide A and Ginkgolide B have the advantages of good separating degree with better linear relation, reproducibility, precision, stability, and recovery rate. The dosage form of the preparations provided by the present invention is beneficial for improving the bioavailability in vivo and drug efficacy.
Group A (Myofascial release technique) on low back 3 repetitions (30 second rest between reps), lasting for 30 s for each myofascial track for 1 set to targeted muscles (plantar fascia, gastrocnemius, hamstrings, and erector spinae). The position will be held for 10-15 seconds when a pain point is found lacrosse ball excellent for this type of massage because their surface area is much less than that of foam rollers.
Efforts to develop gene therapy for long-term treatment of neovascular disease are hampered by ongoing concerns that biologics against vascular endothelial growth factor (VEGF) inhibit both physiological and pathological angiogenesis and are therefore at elevated risk of adverse side effects. A potential solution is to develop disease-targeted gene therapy. Secretogranin III (Scg3), a unique disease-restricted angiogenic factor described by our group, contributes significantly to ocular neovascular disease. We have shown that Scg3 blockade with a monoclonal antibody Fab fragment (Fab) stringently inhibits pathological angiogenesis without affecting healthy vessels. Here we tested the therapeutic efficacy of adeno-associated virus (AAV)-anti-Scg3Fab to block choroidal neovascularization (CNV) induced by subretinal injection of Matrigel in a mouse model. Intravitreal AAV-anti-Scg3Fab significantly reduced CNV and suppressed CNV-associated leukocyte infiltration and macrophage activation. The efficacy and anti-inflammatory effects were equivalent to those achieved by positive control AAV-aflibercept against VEGF. Efficacies of AAV-anti-Scg3Fab and AAV-aflibercept were sustained over 4 months post AAV delivery. The findings support development of AAV-anti-Scg3 as an alternative to AAV-anti-VEGF with equivalent efficacy and potentially safer mechanism of action.
The straining techniques for the groups were explained by the researcher in line with the process steps in the latent phase. Valsalva straining is supported in 2nd stage of labor. Duration of delivery, perineal trauma status and Apgar Scores were evaluated.
This new method of critical sized long bone defects treatment is under clinical development. Treatment of critical sized bone defects is an actual clinical challenge. The "gold standard" in this case is autologous bone grafting. The method disadvantage is associated with limited donor bone resources. Based on our preliminary clinical trial positive results on use of autologous cultured bone marrow-derived multipotent mesenchymal stromal cells (BM-MSCs) in traumatology, our aim was to develop 3D tissue-engineered bone equivalent transplantation technology for restoration of critical sized bone defects. The proposed 3D-TEBE transplantation for bone defects of critical size treatment expecting to restore the bone integrity, form new bone tissue in a site of bone defect, and reduce the rehabilitation period of a patient.

The data obtained from this study will have practical implications for the treatment of reparative osteogenesis alterations and will be based on the principles of evidence-based medicine
Cellular senescence is a stress response with broad pathophysiological implications. Senotherapies can induce senescence to treat cancer or eliminate senescent cells to ameliorate ageing and age-related pathologies. However, the success of senotherapies is limited by the lack of reliable ways to identify senescence. Here, we use nuclear morphology features of senescent cells to devise machine-learning classifiers that accurately predict senescence induced by diverse stressors in different cell types and tissues. As a proof-of-principle, we use these senescence classifiers to characterise senolytics and to screen for drugs that selectively induce senescence in cancer cells but not normal cells. Moreover, a tissue senescence score served to assess the efficacy of senolytic drugs and identified senescence in mouse models of liver cancer initiation, ageing, and fibrosis, and in patients with fatty liver disease. Thus, senescence classifiers can help to detect pathophysiological senescence and to discover and validate potential senotherapies.
For couples who are prevalent sero-discordant, this will be a CHTC session. For couples who are prevalent concordant HIV-positive, the first visit will be the first Partner Steps session. For couples in which one or both do not know their sero-status or have not tested for HIV in the past 12 months, the first session will be a CHTC session.
The invention relates to medicine, in particular to vascular surgery, and can be used for sclerotherapy of varicose veins of the lower extremities, with congenital vascular malformations, with arteriovenous fistulas, with chronic venous insufficiency (CVI) according to CEAP C1-C6, and other diseases of the vascular system. The technical result from the use of the proposed invention is to increase the effectiveness of sclerotherapy of varicose veins by eliminating the local-traumatic effect on the inner shell of the venous wall and shortening the periods of formation of the connective tissue bundle. As a sclerosing drug, a platelet-rich autologous plasmagel produced by the Plasmolifting technology from a patient blood is used; the preliminary injection points are marked on the patient varicose vein, with patient in a horizontal position, with a 21G-27G needle or with the help of an appropriate cannula into the lumen of the vessel slowly under visual or ultrasound control, 0.3-0.7 ml of plasmagel injected preheated in a thermostat to a temperature of 65-85 °C for 6 minutes. After the first injection, with sequentially moving in the proximal direction, the procedure is repeated at each of the distal target points. In doing so, the position of the tip of the needle in the vessel with each injection is identified by the appearance of dark blood in the syringe during back traction of the syringe plunger. If necessary, the additional extravasal injection of 0.3-0.7 ml of plasmogel is carried out at each proximal point of the proposed border of vessel obliteration, after which compression bandage of adhesive bands is applied to varicose veins or compression stockings of the 2nd class is used.